UNICA IRIS Institutional Research Information System

ORIGA, RAFFAELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 102.028
NA - Nord America 5.205
AS - Asia 964
AF - Africa 13
OC - Oceania 6
SA - Sud America 3
Totale 108.219
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 100.499
US - Stati Uniti d'America 5.178
CN - Cina 576
SE - Svezia 450
UA - Ucraina 439
DE - Germania 217
SG - Singapore 180
FI - Finlandia 137
GB - Regno Unito 134
VN - Vietnam 72
FR - Francia 33
IN - India 31
CA - Canada 27
RU - Federazione Russa 22
BE - Belgio 19
IR - Iran 16
PK - Pakistan 14
NL - Olanda 13
TR - Turchia 13
MY - Malesia 12
TH - Thailandia 11
RO - Romania 10
SI - Slovenia 10
ES - Italia 7
BG - Bulgaria 6
KR - Corea 6
AT - Austria 5
AU - Australia 5
CH - Svizzera 5
EG - Egitto 5
ID - Indonesia 5
IE - Irlanda 5
IL - Israele 5
GR - Grecia 4
HU - Ungheria 4
IQ - Iraq 4
TW - Taiwan 4
CY - Cipro 3
CZ - Repubblica Ceca 3
JO - Giordania 3
BD - Bangladesh 2
BR - Brasile 2
JP - Giappone 2
KE - Kenya 2
LU - Lussemburgo 2
MA - Marocco 2
PL - Polonia 2
CI - Costa d'Avorio 1
CL - Cile 1
DK - Danimarca 1
DZ - Algeria 1
GE - Georgia 1
HK - Hong Kong 1
LK - Sri Lanka 1
MT - Malta 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PS - Palestinian Territory 1
TN - Tunisia 1
Totale 108.219
Salva come PNG Salva come JPEG
Città #
Cagliari 97.325
Uta 2.009
Woodbridge 679
Fairfield 635
Chandler 526
Boardman 364
Houston 359
Nyköping 352
Ashburn 297
Ann Arbor 293
Wilmington 265
Seattle 213
Cambridge 209
Jacksonville 184
Dearborn 178
Boston 102
Rome 99
Shanghai 95
Milan 88
Nanjing 87
Beijing 84
Singapore 68
Helsinki 66
Dong Ket 64
San Diego 54
Guangzhou 36
Naples 33
Hebei 27
Redwood City 27
Sassari 26
Shenyang 23
New York 21
London 20
Changsha 19
Nanchang 19
Turin 19
Brussels 18
Mountain View 17
Toronto 17
Bari 16
Florence 16
Jiaxing 16
Hefei 15
Munich 15
Jinan 14
Livorno 14
Tianjin 14
Los Angeles 13
Seregno 13
Catania 10
Gavirate 10
Gurgaon 10
Norwalk 10
Orange 10
Pune 10
Kunming 9
Ljubljana 9
Padova 9
Quartu Sant'Elena 9
Renton 9
Verona 9
Palermo 8
Taranto 8
Washington 8
Zhengzhou 8
Bangkok 7
Bologna 7
Kuala Lumpur 7
Atlanta 6
Bucharest 6
Genoa 6
Hounslow 6
Messina 6
Millbury 6
Shenzhen 6
Sofia 6
Stockholm 6
Taizhou 6
Wuhan 6
Amsterdam 5
Augusta 5
Brescia 5
Chicago 5
Dublin 5
Ercolano 5
Krefeld 5
Lafayette 5
Paris 5
Vienna 5
Acton 4
Alessandria 4
Auburn Hills 4
Carlsbad 4
Falls Church 4
Guwahati 4
Indiana 4
Kilburn 4
Lecce 4
Ningbo 4
Oristano 4
Totale 105.490
Salva come PNG Salva come JPEG
Nome #
Thalassemia major between liver and heart: Where we are now 3.921
Current growth patterns in children and adolescents with thalassemia major 2.831
A decisional algorithm to start iron chelation in patients with beta thalassemia 2.776
A genetic score for the prediction of beta-thalassemia severity 2.722
Earlier initiation of transfusional and iron chelation therapies in recently born children with transfusion-dependent thalassemia 2.563
Deferasirox and children: From clinical trials to the real world 2.367
The V736A TMPRSS6 polymorphism influences liver iron concentration in non-transfusion-dependent thalassemias 2.226
Changes in HbA2 and HbF in alpha thalassemia carriers with KLF1 mutation 2.059
IFNL3 polymorphisms and HCV infection in patients with beta thalassemia 2.038
Natural history of hepatitis C in thalassemia major: a long-term prospective study 2.024
Causes of hospital admission in children and adults with transfusion-dependent thalassemia in Sardinia, 2000-2015 1.933
The problem of borderline hemoglobin A2 levels in the Screening for β-thalassemia carriers in Sardinia. 1.891
Thalassemia major: who is afraid of serum ferritin below 500 μg/l? 1.875
Longitudinal analysis of heart and liver iron in thalassemia major patients according to chelation treatment 1.844
Differences in the erythropoiesis-hepcidin-iron store axis between hemoglobin H disease and β-thalassemia intermedia 1.790
Quality of life in Sardinian patients with transfusion-dependent Thalassemia: a cross-sectional study 1.779
null 1.759
Investigating the Alpha 1Ncol mutation 1.755
Hematological phenotypes in children according to the α-globin genotypes 1.632
Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders 1.616
Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders 1.533
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major 1.433
Complexity of the alpha-globin genotypes identified with thalassemia screening in Sardinia 1.432
Deferasirox: pharmacokinetics and clinical experience 1.337
β-Thalassemia 1.311
Nuovi farmaci ferrochelanti e nuove strategie di ferro chelazione nella talassemia major 1.250
A complicated disease: What can be done to manage thalassemia major more effectively? 1.233
Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia 1.220
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload 1.206
Alpha-Thalassemia 1.198
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload 1.195
Seasonal variation of pretransfusion hemoglobin levels in patients with thalassemia major 1.190
INTERIM RESULTS FROM A PHASE 2A, OPEN-LABEL, DOSE FINDING STUDY OF SOTATERCEPT (ACE-011) IN ADULT PATIENTS (PTS) WITH BETA-THALASSEMIA 1.105
Polymorphism of S-transferase glutathione gene and a major thalassaemia cardiac iron 1.070
Prospettive in Pediatria 1.064
Clinical and molecular analysis of haemoglobin H disease in Sardinia: Haematological, obstetric and cardiac aspects in patients with different genotypes 1.062
null 1.009
Combined therapy with deferiprone and desferrioxamine in thalassemia major 999
Glutathione S-transferase se gene polymorphism and heart iron overload in Thalassemia major 950
Lack of heart iron overload in patients with thalassemia intermedia. 930
Onset of cardiac iron loading in pediatric patients 911
null 886
Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up 808
Risk factors for haemorrhagic cystitis in beta thalassemic patients undergoing allogeneic haematopoietic stem cell transplant 805
Urinary hepcidin in thalassemic syndromes 802
Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): Results from a four years follow-up 743
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia 688
Pregnancy in Thalassemia 680
α-globin gene quadruplication and heterozygous β-thalassemia: a not so rare cause of thalassemia intermedia 671
Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox 663
Impact of the direct-acting antiviral agents (DAAs) on chronic hepatitis C in Sardinian patients with transfusion-dependent Thalassemia major 660
INTERIM RESULTS FROM A PHASE 2A, OPEN-LABEL, DOSE-FINDING STUDY TO DETERMINE THE SAFETY, EFFICACY, AND TOLERABILITY OF SOTATERCEPT (ACE-011) IN ADULTS WITH BETA-THALASSEMIA 648
Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study 633
Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multicentre nation-wide cohort 622
null 618
Genetic basis, pathophysiology and diagnosis 614
Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study 613
A Phase 2a, Open-Label, Dose-Finding Study To Determine The Safety and Tolerability Of Sotatercept (ACE-011) In Adults With Beta (beta)-Thalassemia: Interim Results 610
Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study 609
Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis 607
Retrospective evaluation of different iron chelators on cardiac T2* 598
DEFERASIROX-DEFEROXAMINE COMBINATION THERAPY REDUCES CARDIAC IRON WITH RAPID LIVER IRON REMOVAL AFTER 24 MONTHS IN PATIENTS WITH SEVERE TRANSFUSIONAL IRON OVERLOAD (HYPERION) 598
null 589
Pathophysiology of beta thalassaemia 586
Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia 583
Beta-Thalassemia. 568
Beta-thalassemia 551
Deferasirox-Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION) 547
Changing patterns of thalassaemia in Italy: a WebThal perspective. 541
null 539
Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias 532
The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions 530
Lack of correlation between serum ferritin and liver iron concentration in beta-zero thalassemia intermedia 527
Pregnancy and β-thalassemia: An Italian multicenter experience 525
Relation between hypogonadism and malocclusion in beta-thalassemia major patients: analysis of 122 subjects 518
Renal safety under long-course deferasirox therapy in iron overloaded transfusion-dependent β-thalassemia and other anemias 516
Cholelithiasis in thalassemia major 513
Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment 508
Neutropenia in patients with thalassemia major. 507
Sudden cardiac failure in a β-thalassemia major patient receiving chemotherapy for acute promyelocytic leukemia [5] 507
GDF15 and Erythroferrone Mark Erythropoietic Response to ACE-011 (Sotatercept) in Thalassemia 459
Prima e dopo la splenectomia: terapia combinata in un paziente con compromissione cardiaca secondaria all'accumulo di ferro. 458
Amustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemia 456
Incidence of cancer and related deaths in hemoglobinopathies: A follow-up of 4631 patients between 1970 and 2021 455
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial 454
Selecting ß-Thalassemia Patients for Gene Therapy: A Decision-Making Algorithm 452
Transfusion Therapy in a Multi-Ethnic Sickle Cell Population Real-World Practice. a Preliminary Data Analysis of Multicentre Survey 449
Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited 449
Hemoglobin Utilization in Asplenic and Non-Splenectomized Transfusion Dependent Thalassemia Patients Supported with Pathogen Reduced Red Blood Cell Concentrates in a Phase 3 Study (SPARC) 448
null 435
Crushed deferasirox film-coated tablets in pediatric patients with transfusional hemosiderosis: Results from a single-arm, interventional phase 4 study (MIMAS) 429
EPO and hepcidin plasma concentrations in blood donors and β-thalassemia intermedia are not related to commercially tested plasma ERFE concentrations 427
null 383
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study 379
Densità minerale ossea e rischio di frattura nella _ talassemia major 373
Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies 369
Gene Therapy for Beta Thalassemia: Preliminary Results from the PHASE I/II Tiget-Bthal Trial of Autologous Hematopoietic Stem Cells Genetically Modified with GLOBE Lentiviral Vector 362
No evidence of cardiac iron in 20 never or minimally transfused patients with thalassemia intermedia 358
Management of thalassemia major 358
Mortality in β-thalassemia patients with confirmed pulmonary arterial hypertension on right heart catheterization 355
Totale 100.210
Salva come PNG Salva come JPEG
Categoria #
all - tutte 141.477
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 141.477
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202017.968 0 0 0 401 7.609 5.237 2.577 631 364 266 371 512
2020/202123.558 539 683 777 8.498 5.556 1.885 1.322 973 413 836 991 1.085
2021/20228.150 715 540 416 589 916 841 360 487 508 817 1.092 869
2022/202311.368 1.034 1.395 1.223 756 1.008 953 471 1.504 723 737 1.026 538
2023/202413.514 644 557 523 952 1.107 2.317 2.438 854 655 1.002 1.156 1.309
2024/202514.085 4.381 4.815 4.101 788 0 0 0 0 0 0 0 0
Totale 108.752